Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

Ali, Hammad; Donovan, Basil; Wand, Handan; Read, Tim; Regan, David G.; Grulich, Andrew E.; Fairley, Christopher K.; Guy, Rebecca

doi:10.1136/bmj.f2032

Cited by 385 publications

(317 citation statements)

References 16 publications

Supporting

Mentioning

278

Contrasting

Unclassified

Order By: Relevance

“…6 Data from Australia, the United States and the United Kingdom have shown that the vaccine is effective, with population level reductions in rates of genital warts, HPV and cervical cancer lesions. [7][8][9][10] Recent data from a populationbased study in the US, where HPV vaccine uptake has been <40%, found a reduction in HPV vaccine-type prevalence from 11.5% to 5.1% pre-and post-vaccine, respectively. 11 In Canada, between 2007 and 2009 all provinces and territories launched school-based HPV vaccine programs.…”

mentioning

confidence: 99%

Reduction in cervical intraepithelial neoplasia in young women inBritishColumbia after introduction of theHPVvaccine: An ecological analysis

Naus

Money

Dobson

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

We report on the rates of cervical intraepithelial neoplasia (CIN) in young women aged 15-22 years of age in British Columbia before and after the introduction of an HPV vaccine program. Rates of cervical intraepithelial neoplasia (CIN) 21 for each age stratum (15)(16)(17)(18)(19)(20)(21)(22) in the calendar years 2004-2012 for the province of British Columbia were obtained from the BC Cancer Agency's population-based cervical cancer program. Incidence rate ratios (IRR) of CIN21 were described and compared before and after HPV vaccine program introduction in cohorts born in vaccine eligible years, and in non-vaccine eligible years using piece-wise Poisson regression analysis, and adjusted for age. Between 2004 and 2012, rates of CIN2 and CIN21 in young women aged 15-22 years in the province of British Columbia have decreased overall. After the introduction of the HPV vaccine program, the age adjusted IRR for CIN21 for young women aged 15-17 years decreased significantly from 0.91 (95% CI: 0.86-0.98 p < 0.01) to 0.36 (95% CI: 0.18-0.73 p < 0.01). During the same time period, no similar reduction was found in young women 18-22 years. After introduction of HPV vaccine program, IRR for CIN21 in young women 15-17 was significantly reduced for CIN21 (0.14; 95% CI: 0.04-0.47; p < 0.01) and CIN2 (0.1; 95% CI: 0.02-0.54; p < 0.01). This ecological analysis shows a significant reduction in CIN21 lesions in young women aged 15-17 years in British Columbia after the introduction of the HPV vaccine in young women despite vaccine uptake levels below 70%.The HPV vaccine is one of the most important innovations in cancer prevention. Randomized trials have shown that both the quadrivalent and bivalent HPV vaccines are highly efficacious in preventing HPV infection, cervical dysplasia, anal dysplasia and in the case of the quadrivalent vaccine, genital warts.

show abstract

mentioning

confidence: 99%

Reduction in cervical intraepithelial neoplasia in young women inBritishColumbia after introduction of theHPVvaccine: An ecological analysis

Naus

Money

Dobson

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…12 Targeted vaccination of MSM has been shown to be cost-effective up to and beyond the age of 26 years. 13,14,15 Emerging evidence suggests that HPV-4v may provide additional benefits in older sexually experienced MSM who have previous exposure to HPV by reducing high grade anal lesions (HGAIN) progression and recurrence among MSM.…”

Section: Introductionmentioning

confidence: 99%

HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland

Sadlier

Lynam

O’Dea

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background Men who have sex with men (MSM), particularly HIV-infected MSM are disproportionately affected by HPV infection and associated disease. The HPV vaccine has potential to greatly reduce the burden of HPV-associated disease including anal cancer in MSM. The efficacy of the HPV vaccine is dependent on high levels of vaccine uptake. The aim of this study was to examine HPV vaccine acceptability and factors influencing vaccine acceptability in MSM in Ireland. Methods A self-administered survey was distributed to HIV-infected and HIV negative MSM examining HPV vaccine acceptability and factors associated with vaccine acceptability. Logistic regression was used to identify key variables and predictors of HPV vaccine acceptability. Results 302 MSM participated in the study. Acceptability of HPV vaccine was 31% (unconditional), 51% (conditional on stated efficacy and a cost of €300), 65% (conditional on stated efficacy and a cost of €100) and 78% (conditional on stated efficacy and no cost). Cost was negatively associated with HPV vaccine acceptability (p<0.01) while knowledge of HPV vaccine efficacy was significantly associated with vaccine acceptability, even in the context of associated cost (p<0.01). Conclusions Acceptability of HPV vaccine in MSM in Ireland is high based on no cost vaccine and on stated vaccine efficacy (78%). Cost is negatively associated with vaccine acceptability. Understanding levels of knowledge of HPV infection, HPV associated disease and attitudes toward HPV vaccination are important as they will contribute to HPV vaccine acceptability among MSM and will help guide effective preventive programs.

show abstract

“…24 Our observed safety findings are also similar to that of other studies, whereby vaccine recipients have higher rates of injection site pain, erythema and swelling, but similar rates of systemic AEs. 32 Given the high vaccine efficacy seen in the clinical trials, and the fact that in the 8 y since its original licensure, the qHPV vaccine has been shown to be highly effective at the population level, with marked reductions in the prevalence of HPV vaccine-type related infection and disease in many countries, [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] our findings suggest the vaccine should be equally effective in sub-Saharan African women.…”

mentioning

confidence: 99%

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Mugo

Ansah

Marino

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

Abstract: Objective To measure the effect on genital warts of the national human papillomavirus vaccination programme in Australia, which started in mid-2007.

Cited by 385 publications

References 16 publications

Reduction in cervical intraepithelial neoplasia in young women inBritishColumbia after introduction of theHPVvaccine: An ecological analysis

Reduction in cervical intraepithelial neoplasia in young women inBritishColumbia after introduction of theHPVvaccine: An ecological analysis

HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Contact Info

Product

Resources

About